Teladoc Health, Inc. (NYSE:TDOC) Q2 2023 Earnings Call Transcript July 25, 2023 4:30 PM ET

Company Participants

Patrick Feeley - Head of Investor Relations

Jason Gorevic - Chief Executive Officer

Mala Murthy - Chief Financial Officer

Conference Call Participants

Sandy Draper - Guggenheim

Jailendra Singh - Truist Securities

Lisa Gill - JP Morgan

Daniel Grosslight - Citi

Sean Dodge - RBC Capital Markets

Jessica Tassan - Piper Sandler

Richard Close - Canaccord Genuity

George Hill - Deutsche Bank.

Charles Rhyee - TD Cowen

Ryan Daniels - William Blair

Scott Schoenhaus - KeyBanc

Stan Berenshteyn - Wells Fargo

Kevin Caliendo - UBS.

David Larsen - BTIG

Elizabeth Anderson - Evercore

Vikram Kesavabhotla - Baird

Operator

Hello, and welcome to the Teladoc Second Quarter 2023 Earnings Conference Call. My name is Alex, I'll be coordinating the call today. [Operator Instructions]

I'll now hand it over to your host, Patrick Feeley, Head of Investor Relations. Please go ahead.

Patrick Feeley

Thank you, and good afternoon. Today after the market closed, we issued a press release announcing our second quarter 2023 financial results. This press release and the accompanying slide presentation are available on the Investor Relations section of the teladochealth.com website. On this call to discuss the results are Jason Gorevic, Chief Executive Officer; and Mala Murthy, Chief Financial Officer.

During this call, we will also discuss our third quarter full year 2023 outlook and our prepared remarks will be followed by a question-and-answer session. Please note that we will be discussing certain non-GAAP financial measures that we believe are important in evaluating Teladoc Health’s performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release that is posted on our website.

Also, please note that certain statements made during this call will be forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause the actual results for Teladoc Health to differ materially from those expressed or implied on this call. For additional information, please refer to our cautionary statement on our press release and our filings with the SEC, all of which are available on our website.

I would now like to turn the call over to Jason.

Jason Gorevic

Thank you, Patrick, and thanks everyone for joining us. This afternoon, we are pleased to report a strong second quarter with results that met or exceeded all of our financial and operating guidance. It's a reflection of the strength and stability we've seen across the business and why we're raising the low end of our revenue and adjusted EBITDA guidance for the rest of the year.